A New Challenge for HIV Survivors: The Cardiovascular-Kidney-Metabolic (CKM) Syndrome.
As life expectancy for people with HIV (PWH) continues to increase due to advancements in antiretroviral therapy (ART), a concerning new health issue is emerging: the Cardiovascular-Kidney-Metabolic (CKM) syndrome. This complex condition presents a significant challenge, yet it remains poorly understood. This article will delve into the intricacies of CKM syndrome in PWH, exploring its causes, the challenges it presents, and the call for further research.
Understanding the Syndemic:
CKM syndrome is not just one disease; it's a combination of cardiovascular, kidney, and metabolic disorders. In PWH, several factors contribute to this syndrome. Chronic inflammation, alterations in how the body processes drugs (pharmacokinetics), the metabolic effects of ART, and imbalances in gut bacteria (dysbiosis) all increase the risk. These factors can interact in complex ways, making the syndrome difficult to manage.
The Challenges of Management:
Managing CKM syndrome often requires multiple medications. This increased medication burden elevates the risk of drug-drug interactions and adverse drug effects. This is a critical concern for PWH, as it can lead to serious health complications and reduce the effectiveness of ART.
A Call for Action:
Recognizing the growing importance of CKM syndrome in PWH, a perspective published in Clinical Pharmacology & Therapeutics highlights the gaps in our knowledge and calls for increased research. This research is crucial to better understand the syndrome, develop effective treatments, and improve the quality of life for PWH.
Key Takeaways:
- CKM Syndrome: A combination of cardiovascular, kidney, and metabolic disorders.
- Risk Factors: Inflammation, altered drug processing, ART-related metabolic effects, and gut dysbiosis.
- Challenges: Increased medication burden, drug interactions, and adverse effects.
- Need for Research: Further investigation is essential to address the challenges posed by CKM syndrome in PWH.
Additional Information:
- It Starts and Ends with Us: Community at the Centre of Clinical Studies (Information available on the EATG website).
- Donate (Information available on the EATG website).
- Get Involved (Information available on the EATG website).
- Subscribe (Information available on the EATG website).
- Comorbidities (Information available on the EATG website).
Recent News and Studies:
- December 9, 2025: New data from EACS 2025 on quality of life and comorbidities in people with HIV (Information available on the EATG website).
- November 30, 2025: CATIE: TreatmentUpdate 256: Long-acting HIV treatment, hepatitis C, sleep (Information available on the EATG website).
- November 30, 2025: New study identifies immune markers that may predict cancer development in people living with HIV (Information available on the EATG website).
Get Involved:
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
- Become a member (Information available on the EATG website).
- Support us (Information available on the EATG website).
Subscribe:
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.
- EATG Newsletter (Information available on the EATG website).
- HIV&Co-infections Bulletin (Information available on the EATG website).
Controversy & Comment Hooks:
Could the long-term effects of ART be underestimated in contributing to CKM syndrome? What are your thoughts on the balance between extending life through ART and the potential for increased health complications later on? Share your opinions and experiences in the comments below!
